Stay updated on PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Sign up to get notified when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.

Latest updates to the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedA minor update to the record history shows a new revision v3.4.2 added and v3.4.1 removed, with no substantive study content affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check20 days agoChange DetectedThe Record History shows a new revision (v3.4.1) added and the previous revision (v3.4.0) removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe new version adds a glossary toggle and color-coded change highlights (green for additions, red for deletions) with an updated revision notice (v3.4.0). The old revision note (v3.3.4) and the 'No FEAR Act Data' text were removed.SummaryDifference1%

- Check42 days agoChange DetectedA new revision entry is added to the Record History: Revision: v3.3.4. This is a routine site revision update and does not modify trial data or study details.SummaryDifference0.1%

- Check49 days agoChange DetectedRecord History now lists the latest known status and sponsor (Jiangsu HengRui Medicine Co., Ltd.) with a 2022-10 date, and includes Recruitment Status and Study Status details as of 2022-11-16.SummaryDifference0.9%

- Check63 days agoChange DetectedA new revision label (Revision: v3.3.3) was added to the History. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

Stay in the know with updates to PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Camrelizumab + Famitinib Clinical Trial page.